Salvador IIJ, Pizaña DA, Ramírez REF

Language: Spanish
References: 19
Page: 63-67
PDF size: 236.19 Kb.

ABSTRACT

The frequency of thromboembolic events in patients with coronavirus disease is high, however it is still unknown what is the appropriate way to identify people at higher risk of thrombotic complications and define who can benefit from a more aggressive treatment, beyond the standard thromboprophylaxis. A large proportion of critically ill patients with coronavirus have a hypercoagulable thromboelastography profile with damage related to fibrinogen and platelet function; most patients have a high maximum amplitude on thromboelastography. A review of thromboelastograms of 11 critically ill patients due to SARS-CoV-2 was made to characterize their coagulation status. A 36.36% hypercoagulability was found in thromboelastography, mainly with native citrate, despite treatment with low molecular weight heparin at therapeutic doses. The predominant hypercoagulable profile was not associated with platelet function since the MA (maximum amplitude) remained within normal limits.

REFERENCES

1. Center for Systems and Science Engineering at Johns Hopkins University. COVID-19 dashboard. https://coronavirus.jhu.edu/map.html

2. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281-292.e6.

3. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669-677.

4. Moser KM, LeMoine JR, Nachtwey FJ, Spragg RG. Deep venous thrombosis and pulmonary embolism frequency in a respiratory intensive care unit. JAMA. 1981;246:1422-1424.

5. Geerts W, Cook D, Selby R, Etchells E. Venous thromboembolism and its prevention in critical care. J Crit Care. 2002;17:95-104.

6. Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res. 2019;105:93-116.

7. Park JE, Li K, Barlan A, Fehr AR, Perlman S, McCray Jr PB, et al. Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc Natl Acad Sci USA. 2016;113(43):12262-12267.

8. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(1):34-45.

9. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020;18(7):1559-1561.

10. López MS. Tromboelastografía y tromboelastometría para el monitoreo del tratamiento en pacientes con sangrado en distintos escenarios clínicos. Hematología. 2018;2:278-291.

11. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145-148.

12. Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis. Thromb Haemost. 2020;120(5):876-878.

13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.

14. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92(7):791-796.

15. Lippi G, Salvagno GL, Ippolito L, Franchini M, Favaloro EJ. Shortened activated partial thromboplastin time: causes and management. Blood Coagul Fibrinolysis. 2010;21:459-463.

16. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.

17. Yuriditsky E, MD, Horowitz JM, Merchan C, Ahuja T, Brosnahan SB, McVoy L, et al. Thromboelastography profiles of critically ill patients with coronavirus disease 2019. Crit Care Med. 2020;48(9):1319-1326. doi: 10.1097/CCM.0000000000004471.

18. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 2000;88:1474-1480.

19. Gozzo L, Viale P, Longo L, Vitale DC, Drago F. The potential role of heparin in patients with COVID-19: beyond the anticoagulant effect. A review. Front Pharmacol. 2020;11:1307. doi: 10.3389/fphar.2020.01307.